PCV13: Clinical Trials

9 trials of PCV13, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 unknown. 9 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 39Completed 8, Unknown 1
Phase 22Completed 2

Follow PCV13: new trials by email Literature Review of PCV13 trials Research Report on PCV13

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)
V114, PCV13 - Pneumococcal Infections
Phase 3CompletedMerck Sharp & Dohme LLC6942020-07-012023-07-28
Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)
V114, Prevnar 13® - Pneumococcal Infections
Phase 3CompletedMerck Sharp & Dohme LLC6062019-06-252023-01-13
CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study
PCV13 - Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection
Phase 2 / Phase 3CompletedUniversity of British Columbia2482018-08-232024-03-04
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections
Phase 3CompletedMerck Sharp & Dohme LLC15152018-07-162021-01-15
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)
V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections
Phase 3CompletedMerck Sharp & Dohme LLC6522018-06-222021-11-02
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older
HZ/su vaccine GSK1437173A, Prevenar13 - Herpes Zoster
Phase 3CompletedGlaxoSmithKline9132018-04-122022-01-11
Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers
MenACYW conjugate vaccine, MMR, Varicella - Meningitis, Meningococcal
Phase 3CompletedSanofi Pasteur, a Sanofi Company11832016-11-072022-04-05
Protecting From Pneumococcus in Early Life (The PROPEL Trial)
13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid, placebo 0.9% sodium chloride plus tetanus toxoid, tetanus toxoid - Pneumonia
Phase 3UnknownLondon School of Hygiene and Tropical Medicine6002016-03-112020-10-23
Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam
PCV10, PCV13 - Pneumococcal Vaccines
Phase 2 / Phase 3CompletedMurdoch Childrens Research Institute14002013-09-302022-09-14

Conditions studied

Pneumococcal Infections (5)  ·  Herpes Zoster (1)  ·  Meningitis (1)  ·  Meningitis, Meningococcal (1)  ·  Meningococcal Infections (1)  ·  Pneumonia (1)

Sponsors

Merck Sharp & Dohme LLC (4)  ·  GlaxoSmithKline (1)  ·  London School of Hygiene and Tropical Medicine (1)  ·  Murdoch Childrens Research Institute (1)  ·  Sanofi Pasteur, a Sanofi Company (1)  ·  University of British Columbia (1)

Countries

Canada (3)  ·  Russia (3)  ·  United States (3)  ·  Poland (2)  ·  South Korea (2)  ·  Thailand (2)  ·  Australia (1)  ·  Chile (1)  ·  Estonia (1)  ·  Finland (1)  ·  Germany (1)  ·  Japan (1)  ·  Malaysia (1)  ·  Mexico (1)  ·  New Zealand (1)

Top investigators

Ed Clarke, MB (1)  ·  Edward K Mulholland, MBBS, FRACP (1)  ·  Manish Sadarangani, MD (1)

Results publications

PMID 29884695, PMID 30975525, PMID 33745731, PMID 33814028, PMID 34171233, PMID 34489128, PMID 34963639, PMID 35146039, PMID 36150974, PMID 36785850, PMID 37344262, PMID 40537903, PMID 41442837

NIH funding

2017 (3), 2018 (1), 2019 (1)